Ccr4 - C-C motif chemokine receptor 4 Gene

Also Known as Cmkbr4

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 171054

About Ccr4

Primary_assembly 8: 114,176,974-114,178,056 reverse strand.mRatBN7.2:CM026981.1

This gene has 1 transcript (splice variant), 114 orthologues, 24 paralogues and is associated with 12 phenotypes.

Summary

Predicted to enable C-C chemokine binding activity and C-C Chemokine Receptor activity. Involved in several processes, including positive regulation of positive chemotaxis; response to antibiotic; and response to bacterium. Located in neuronal cell body. Biomarker of asthma and pulmonary fibrosis. Orthologous to human CCR4 (C-C motif Chemokine Receptor 4). [provided by Alliance of Genome Resources, Apr 2022]

Ccr4 Products (1)

mRNA Protein Name
NM_133532.3 NP_598216.3 C-C chemokine receptor type 4

Gene Ontology

  • Biological Process
  • Cellular Component
Biological Process GO Annotation Evidence References Source
involved in positive regulation of positive chemotaxis IDA
IDA: Inferred from direct assay
12651599 RGD
involved in response to bacterium IEP
IEP: Inferred from expression pattern
14727120 RGD
Cellular Component GO Annotation Evidence References Source
located in neuronal cell body IDA
IDA: Inferred from direct assay
11438578 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

C-C chemokine receptor type 4

  • C-C chemokine receptor 4

  • chemokine (C-C motif) receptor 4

  • chemokine (C-C) receptor 4

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive MoleculesInhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P99253 Mogamulizumab Inhibitor 96.9% Unkown

Clinical Phase

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Phase
HY-148074 Zelnecirnon Inhibitor 99.71% Phase 2
HY-148494 Tivumecirnon Antagonist 99.48% Phase 2
HY-100183 GSK2239633A Antagonist 99.81% Phase 1

Pre-clinical Phase

Bioactive Molecules (12)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-U00064 AZD2098 Inhibitor 99.91% Unkown
HY-103364A C-021 dihydrochloride Antagonist 99.73% Unkown
HY-103364 C-021 Inhibitor 99.95% Unkown
HY-157453 CCR4 antagonist 4 Antagonist 98.92% Unkown
HY-P3418 CKLF1-C27 Inhibitor 98.02% Unkown
HY-P3982 CKLF1-C19 Chemical 99.11% Unkown
HY-131349 CCR4-351 Antagonist 98.95% Unkown
HY-131349A CCR4-351 hydrochloride Antagonist 98.14% Unkown
HY-147385 CCR4 antagonist 3 Antagonist 99.94% Unkown
HY-122565 GSK-2239633 Antagonist / Unkown
HY-P3418A CKLF1-C27 TFA Inhibitor / Unkown
HY-182564 ST45177901 Antagonist / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Ccr4 NCBI NCBI:1233